Search

A study conducted at Zhejiang International Studies University in Hangzhou, China, explores the propagation dynamics of a spatial discrete virus model with HIV viral load and 2-LTR dynamics during high active antiretroviral therapy. The researchers establish the existence of traveling wave solutions for the virus model when the basic reproduction number is greater than one and the wave speed is not less than a threshold speed. They also prove the nonexistence of traveling wave solutions when the basic reproduction number is smaller than one or larger than one but the wave speeds are less than the threshold speed. The study concludes that certain inhibitors can decrease the minimum wave speed, while the diffusion rate of viruses will increase it. [Extracted from the article]

A recent study conducted by researchers at Beijing University of Chinese Medicine explores the potential of bile acids (BAs) as antiviral drugs. The study focuses on chenodeoxycholic acid (CDCA) and its receptor, farnesoid X receptor (FXR), which negatively regulates interferon signaling and limits the effectiveness of CDCA in inhibiting virus replication. The researchers found that FXR deficiency or pharmacological inhibition enhances interferon signaling activation, leading to a more potent ability of CDCA to restrict virus infection. These findings suggest that targeting FXR inhibition could be a promising strategy for the clinical application of BAs metabolites as antiviral drugs. [Extracted from the article]

A patent has been issued for compositions and methods to control mosquito-borne viruses. The patent focuses on inhibiting the transmission of viruses such as Dengue, Zika, and Chikungunya by using RNA interference (RNAi) to inhibit the expression of specific mosquito genes. The method involves administering an RNAi agent to Aedes aegypti mosquitoes or larvae, which reduces the viral load in the mosquitoes. The patent also mentions the use of Wolbachia bacteria and modified mosquitoes as potential strategies for controlling these viruses. [Extracted from the article]

A preprint abstract discusses the role of viral interference in disrupting biennial respiratory syncytial virus (RSV) epidemics in northern Stockholm. RSV primarily affects infants and older adults, with seasonal outbreaks in temperate countries. After the 2009 influenza pandemic, the biennial pattern of RSV activity in northern Stockholm shifted, with early/large outbreaks in even-numbered years and late/small outbreaks in odd-numbered years. The study found that viral interference from influenza was the only mechanism that explained this change in pattern. The research highlights the complex interactions between respiratory viruses and has implications for future public health interventions. [Extracted from the article]

A recent study conducted by the Robert Koch Institute in Berlin, Germany, explores the potential role of temperature in regulating the replication of the Ebola virus. The study focuses on the Angolan free-tailed bat (Mops condylurus), which is believed to be a likely reservoir for the virus. The researchers found that cells from M. condylurus were highly tolerant to temperature variations, and that Ebola virus replication was temperature-dependent, with reduced efficiency at lower temperatures. The study suggests that heterothermy, the ability to regulate body temperature, may play a role in tolerating Ebola virus infections in bats. [Extracted from the article]

This document provides information about a clinical trial that is currently recruiting participants. The trial aims to test the safety and effectiveness of a drug called olutasidenib in preventing the relapse of certain types of leukemia in patients who have undergone donor hematopoietic cell transplant. The trial will evaluate various outcomes such as overall survival and the incidence of adverse events. It is set to begin on October 5, 2024, and will follow patients for up to 2 years. The document includes eligibility criteria for participants and contact information for those interested in participating. [Extracted from the article]

A recent study conducted by the University of California San Francisco (UCSF) examined the extent, trends, and impact of acquired drug resistance (ADR) in individuals with HIV/AIDS in Rhode Island from 2004 to 2021. The study found that overall ADR to any drug decreased during this time period, with decreases observed in nucleoside reverse transcriptase inhibitors, nonnucleoside reverse transcriptase inhibitors, protease inhibitors, and integrase strand transfer inhibitors. The study also found that males and those exposed to more antiretroviral therapy regimens were more likely to have multi-class resistance. The researchers concluded that while there have been reassuring declines in ADR, continued monitoring is necessary to maintain antiretroviral success, especially with the increasing use of integrase strand transfer inhibitors and 2-drug and long-acting formulations. [Extracted from the article]

A recent study conducted by researchers at Johns Hopkins University examined the consequences of low-level viremia (LLV) among women with HIV in the United States from 2003 to 2020. The study found that women with LLV had an increased risk of virologic failure, with persistent LLV (pLLV) showing the highest risk. However, there was only a trend towards increased risk of multimorbidity among women with pLLV. The findings highlight the need for further research and interventions to address the potential clinical sequelae of LLV among women with HIV. [Extracted from the article]

A recent systematic review and meta-analysis conducted by researchers at the Department of Reproductive Health in Ethiopia found that approximately half of people living with HIV/AIDS in Ethiopia experience poor sleep quality. The study identified several factors associated with poor sleep quality, including depression, a low CD4 count, a high viral load, and anxiety. The researchers recommend that policymakers and relevant organizations address these issues in order to improve sleep quality and manage the factors affecting it. This information is important for library patrons conducting research on HIV/AIDS and its impact on sleep quality in Ethiopia. [Extracted from the article]

A study conducted at Kenyatta National Hospital in Nairobi, Kenya, examined the adherence to antiretroviral therapy (ART) among adolescents living with HIV (ALH) in boarding schools compared to day schools. The researchers collected data from ALH aged 14-19 years in 25 HIV clinics in Kenya and found that ALH in boarding schools were more likely to self-report missing ART compared to those in day schools. Additionally, only 60% of ALH had undetectable HIV viral load. The study suggests that schools could play a crucial role in improving outcomes for ALH. [Extracted from the article]

The article focuses on a new clinical trial (NCT06548412) investigating the addition of CTX-009 to the standard therapy for patients with unresectable or metastatic biliary tract cancers. Topics include the trial's objectives to evaluate safety and efficacy, the combination of CTX-009 with gemcitabine, cisplatin, and durvalumab, and the study's design and recruitment status.

The article focuses on a new clinical trial, ACT-Together (NCT06549153), which aims to evaluate a group-based educational intervention designed to enhance adherence to recommended cancer surveillance and risk-reducing procedures among medically underserved women and racial/ethnic minorities with BRCA 1 and 2. Topics include the trial's objectives of improving cancer screening rates and evaluating participant satisfaction with the intervention.

A study analyzed the viral load of HIV in the colostrum (first milk) of postpartum women living with HIV who were using antiretroviral therapy (ART). The research found that six out of nine samples analyzed had undetectable levels of the virus, while three samples had levels below the detection limit. The study suggests that achieving undetectable or low levels of HIV in colostrum is possible with ART, but further research is needed to understand the transmission potential of breast milk in women living with HIV. The study emphasizes the importance of prenatal HIV screening and ART in reducing the risk of HIV transmission during pregnancy and breastfeeding. [Extracted from the article]

A recent study conducted by researchers at the University of Medicine and Pharmacy in Bucharest, Romania, explored the associations between microRNAs and viral load in patients with chronic hepatitis B. The study utilized a systematic review and meta-analysis approach, analyzing data from five databases. The findings suggest that microRNAs, particularly miR-122 and miR-192-5p, are significantly associated with HBV-DNA levels. However, further in vivo assessment is needed to fully understand the connections between non-coding molecules and viremia levels. This study provides valuable insights into potential pathways for developing new inhibitors of the viral replication cycle. [Extracted from the article]

A recent study conducted at the Medical City in Baghdad aimed to examine the association between hepatitis C virus (HCV) infection and interleukin-17 (IL-17) levels. The study included 50 HCV patients and 50 controls, and measured serum levels of IL-17 and viral load of HCV. The results showed that the concentration of IL-17 was significantly higher in HCV patients, particularly in older patients. However, there was no significant difference in the readings of HCV viral load and IL-17. This study provides new insights into the role of IL-17 in chronic HCV infection and its potential contribution to liver fibrosis development. [Extracted from the article]

A recent report from Xinyang Normal University in China discusses the dynamics of an age-structured multiscale model of the Hepatitis C Virus (HCV) and its response to direct-acting antiviral agents (DAAs). The model incorporates various factors such as intracellular virus replication, modes of virus transmission, and antibody immune response. The researchers found that monitoring viral load decline after DAA treatment is crucial for determining subsequent treatment regimens. The study suggests that blocking cell-to-cell infection and enhancing the antibody immune response can effectively reduce viral load and potentially eradicate the infection. [Extracted from the article]

Researchers from Heilongjiang University of Traditional Chinese Medicine have conducted a review on the function of microRNAs (miRNAs) in the interaction between human infectious viruses and host cells. miRNAs are small non-coding RNAs that can regulate gene expression and play a role in various cellular processes. Both viruses and host cells can encode miRNAs, which can either inhibit or facilitate virus replication. This review aims to provide insights into viral pathogenic mechanisms and potential therapeutic approaches. For more information, readers can refer to the original research article. [Extracted from the article]

A recent study conducted by the School of Pharmaceutical Sciences in Shizuoka, Japan, has focused on the development of direct-acting antivirals (DAAs) to target the mumps virus (MuV). The researchers synthesized MuV sialidase inhibitors, compounds that can inhibit viral replication and infection. These inhibitors showed higher specificity for MuV and were more effective than existing inhibitors. The study provides valuable insights for the development of highly potent sialidase inhibitors as potential antivirals against MuV. [Extracted from the article]

A recent study conducted at the University of Sydney in Australia examined the effectiveness of various antiviral treatments for cats infected with feline leukemia virus (FeLV). The study found that none of the treatments tested were effective in treating FeLV infections. The median survival time for cats receiving antiviral therapy was 634 days, compared to 780 days for untreated cats. The study also identified age at diagnosis and viral load as important prognostic markers for survival. The researchers recommend further studies using multiple drugs from different classes to explore antiretroviral therapy for FeLV-positive cats. [Extracted from the article]

This document provides information about a research study conducted by Yale University in collaboration with the National Institute of Mental Health and the Fogarty International Center of the National Institute of Health. The study aims to develop a strategy for reducing stigma in people who inject drugs (PWID) with HIV using a rapid start antiretroviral therapy intervention (RS-ART). The study will utilize the Delphi method and interviews with experts and PWID to develop the implementation strategy, which will then be pilot tested in a randomized controlled trial. The focus of the trial is on how soon providers are able to prescribe ART after diagnosis, rather than the type of medication and dose prescribed. The trial will also measure outcomes related to HIV stigma and substance use stigma. The study is not yet recruiting participants and is expected to be completed by August 2026. [Extracted from the article]

A recent study conducted by the University of South Carolina explored the association between sexual orientation, gender identity, and virologic failure among people with HIV (PWH) in the United States. The study used data from the All of Us (AoU) Research Program, which aims to improve health and health equity by partnering with one million participants. The findings revealed that cisgender sexual minority women were at a higher risk of HIV virologic failure compared to cisgender heterosexual women. The study suggests that frequent viral load monitoring among sexual minority women with HIV is important for early detection and intervention. Further research is needed to understand the specific needs of different subgroups within sexual and gender minorities. [Extracted from the article]

A recent study conducted by the Elizabeth Glaser Pediatric AIDS Foundation in Mozambique examined the rollout of paediatric dolutegravir (pDTG) and its impact on virological outcomes among children living with HIV. The study found that most eligible children initiated pDTG according to guidelines, leading to improved viral load suppression (VLS) post-pDTG. However, challenges were identified, including unexplained switches off pDTG after initiation, low viral load coverage, and inadequate documentation in clinic records. Factors associated with successful VLS included older age and previous VLS. This research provides valuable insights into the real-world challenges of implementing pDTG in resource-limited settings. [Extracted from the article]

This article provides information about a newly launched clinical trial, NCT06526819, conducted by Sumitomo Pharma America, Inc. The trial aims to assess the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of SMP-3124LP in adults with advanced solid tumors. The study will determine the recommended phase 2 dose, evaluate adverse events, and measure the objective response rate. The trial is not yet recruiting and is expected to be completed by May 2029. The eligibility criteria include specific types of cancer, disease progression on standard therapy, and no alternative treatment options. The trial is open to all genders and individuals aged 18 years and above. Contact information is provided for further inquiries. [Extracted from the article]

This document provides information about a clinical trial for the treatment of leiomyosarcoma, a type of cancer. The trial involves the use of two drugs, all-trans retinoic acid (ATRA) and Cemiplimab, administered in specific doses and intervals. The trial is currently not recruiting participants, and the estimated completion date is December 31, 2025. The document also includes eligibility criteria for participants, contact information, and administrative details about the trial. [Extracted from the article]

A recent study conducted by the Paul-Ehrlich-Institute in Germany has provided new insights into the replication of the Ross River virus (RRV). The researchers constructed a recombinant RRV that allowed for real-time imaging of viral replication. They found that the presence or absence of a stop codon after the nsP3 gene did not affect the replication capacity of the virus. However, there was a cell type-dependent delay in RRV replication in HEK 293T cells, which was caused by an inhibitor called ZAP. The study suggests that viral replication of alphaviruses is unique to each virus and dependent on the cell type. [Extracted from the article]

A patent has been issued for a protein purification method and kit developed by Exothera SA. The method combines virus inactivation and purification of a feed containing a protein of interest. The process involves contacting the feed with negatively charged particles or media, conditioning the particles or media to inactivate viruses, and eluting the protein of interest. This method aims to overcome the drawbacks of separate purification and virus inactivation steps, providing a more efficient and streamlined process for antibody manufacturing. [Extracted from the article]

A study conducted at Nicolaus Copernicus University in Bydgoszcz, Poland, analyzed the impact of prophylactic post-transplant rituximab on EBV infection and EBV-PTLD in children after allo-HCT. The study found that prophylaxis with rituximab significantly reduced the occurrence of EBV infection and EBV-PTLD in pediatric patients. The treatment was effective as a preemptive therapy in the majority of cases. However, the occurrence of EBV-PTLD was associated with an increased risk of relapse of primary malignant disease. [Extracted from the article]

This document provides information about a clinical trial for the treatment of acute myeloid leukemia (AML). The trial aims to evaluate the effectiveness of a combination therapy involving iadademstat, venetoclax, and azacitidine. The study will assess measurable residual disease (MRD)-negative complete remission (cCR), event-free survival (EFS), overall survival (OS), and duration of response (DoR). The trial is currently recruiting participants and has specific eligibility criteria. The document also includes administrative details such as the study ID number and principal investigator. [Extracted from the article]

This document provides information about a clinical trial (NCT06522932) conducted by the University of California, San Francisco. The trial aims to investigate the use of 64Cu-GRIP B PET imaging before and after CD19-directed CAR-T therapy in participants with relapsed/refractory non-Hodgkin lymphoma. The trial will involve optional tumor biopsies and the use of the drug 64Cu-GRIP B. The study is not yet recruiting and is expected to be completed by January 31, 2027. The trial is open to participants of all genders aged 18 years and above. The contact person for the trial is Kenya Gomez. The trial is funded by The V Foundation. [Extracted from the article]

A recent report from the University of Maryland provides new insights into the hepatitis E virus (HEV). The study found that the HEV helicase, an enzyme involved in viral RNA synthesis, interacts with a cellular protein called oxysterol binding protein (OSBP). The researchers discovered that silencing OSBP significantly reduced HEV replication, suggesting that OSBP contributes to the replication of the virus. These findings enhance our understanding of the interactions between HEV and host cells. [Extracted from the article]

This document provides information about a clinical trial, NCT06525389, that aims to inform treatment guidelines for HIV-associated talaromycosis. The trial will compare different treatment regimens, including liposomal amphotericin B (LAmB) and conventional deoxycholate amphotericin B (DAmB) for induction therapy, as well as the effectiveness of adding flucytosine (5FC) to amphotericin B. The trial will also investigate whether HIV viral load guided stopping of itraconazole maintenance therapy is as effective as the current CD4 guided strategy in preventing talaromycosis relapse. The trial is expected to be completed by January 6, 2030 and will enroll 428 HIV-infected adults in multiple countries. The data collected will be shared openly with the scientific community. [Extracted from the article]

This article discusses a study conducted at an urban clinic in Kampala, Uganda, which aimed to identify predictors of viral rebound among adolescents with HIV. Viral rebound refers to the increase in viral load after achieving viral suppression. The study found that the overall proportion of viral rebound among the adolescents was 31.5%, with some individuals experiencing multiple rebounds. Factors associated with viral rebound included duration on antiretroviral therapy (ART), psychosocial issues, baseline viral load, and the use of protease inhibitors in ART regimens. The study suggests the importance of screening adolescents for psychosocial challenges and providing appropriate support in HIV care and treatment programs. [Extracted from the article]

A report from Dalian Ocean University discusses the current treatment methods for HIV/AIDS. The study compares antiretroviral therapy (ART) and immunotherapy in terms of viral suppression, immune recovery, and patient quality of life. While ART has been effective in preventing HIV infection and preserving patients' health, there are concerns about long-term drug use and drug resistance. Immunotherapy shows promise in creating novel treatments, but more research is needed to ensure their efficacy. The study suggests that a combination therapy strategy utilizing the strengths of both approaches could enhance HIV control and elimination in the future. [Extracted from the article]

A recent study conducted by the University of Miami focused on Black women living with HIV (BWLWH) and the challenges they face in terms of medication adherence and mental health. The study developed an intervention called STEP-AD (Striving Towards Empowerment and Medication Adherence) based on cognitive behavioral therapy and culturally congruent coping to address these issues. The pilot randomized control trial found that BWLWH who participated in STEP-AD had higher antiretroviral therapy (ART) adherence, lower likelihood of being clinically diagnosed with post-traumatic stress disorder (PTSD), and borderline significance on higher CD4 count compared to those who received enhanced treatment as usual. These findings suggest the preliminary efficacy of STEP-AD in improving ART adherence, mental health, and immune function for BWLWH. [Extracted from the article]

A qualitative study conducted in Uganda aimed to explore the knowledge and perceptions of health-care workers regarding viral load (VL) testing and low-level viremia (LLV) in HIV care. The study involved 15 key informant interviews with health-care workers from high-volume HIV clinics. The findings revealed that health-care workers had a good understanding of VL testing and its benefits, but faced challenges such as lack of transport and long waiting times. They were not familiar with the term "low-level viremia," but recognized that a VL range between 50 and 999 copies/ml was undesirable. The study recommended the implementation of centralized and point-of-care VL testing, as well as comprehensive interventions to manage LLV through targeted health education of health workers. [Extracted from the article]

A recent study conducted by the University of Washington examined the relationship between intimate partner violence (IPV) and health outcomes among people with HIV (PWH) in the United States. The study found that 9.3% of PWH reported experiencing IPV in the past year, with half of them reporting psychological violence without physical or sexual violence. The study revealed that IPV was associated with various negative health outcomes, including unstable housing, higher HIV viral load, depressive symptoms, substance use, and lower adherence to antiretroviral therapy. The findings highlight the importance of addressing psychological IPV in addition to physical and sexual IPV. [Extracted from the article]

A phase III clinical trial is set to begin on February 6, 2025, comparing the effectiveness of pembrolizumab and sacituzumab govitecan to sacituzumab govitecan alone in treating patients with advanced urothelial cancer. The trial aims to assess various outcome measures such as overall survival, progression-free survival, overall response rate, clinical benefit rate, duration of response, and incidence of adverse events. Eligibility criteria for the trial include being at least 18 years old, having an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2, and having locally advanced or metastatic urothelial cancer. The trial is expected to enroll 384 patients and be completed by December 31, 2028. [Extracted from the article]

This document provides information about a clinical trial for the treatment of endometrial cancer. The trial involves the use of two drugs, Avelumab and M1774, and aims to enroll 25 participants. The eligibility criteria for participants include having ARID1A-mutated endometrial cancer and having received prior immunotherapy targeting the PD-1/PD-L1 pathway. The trial is not yet recruiting and is expected to be completed by August 31, 2029. The study is being conducted by the Dana-Farber Cancer Institute in collaboration with EMD Serono and The Applebaum Foundation. [Extracted from the article]

A patent application titled "Intranasal Administration of Cannabigerol, CBDa, CBGa, & Uncaria Tomentosa Hydroalcoholic Extract Compounds Emulsified in Saline Homogenous Solution for Intranasal Administration" has been published online. The inventor, Artis Asahel Clark, proposes a natural, all-organic product delivered intranasally to reduce viral load and spread frequency in the treatment of respiratory viruses, including SARS-CoV-2. The formulation utilizes cannabinoids and uncaria tomentosa hydroalcoholic extract compounds, and it aims to increase the availability of medications for respiratory illnesses while minimizing side effects. The patent application provides detailed claims and descriptions of the therapeutic product formulations. [Extracted from the article]

A recent study conducted by researchers at King Saud University explored the potential role of microRNAs (miRNAs) as biomarkers in the pathogenesis of hepatitis C virus (HCV) infection. The study found that the expression levels of miR-122 and miR-486 were strongly correlated with physical activity, pain perception, and muscle fatigue biomarkers in HCV-infected patients. These miRNAs were also associated with disease severity and oxidative stress, but not with viral load or HCV-RNA expression. The results suggest that miRNAs may impact disease progression and symptoms through host factors rather than directly affecting viral replication, and they could serve as prognostic biomarkers and therapeutic targets for HCV infection. [Extracted from the article]

The patent application titled "Cryptic Proteins Expressed From Defective Viral Genomes Interfere With Influenza Virus Replication" proposes methods for using modified influenza gene products to inhibit wild-type influenza virus replication, stimulate the immune system, and serve as vaccine backbones. The study identifies defective viral genomes (DVGs) that can produce cryptic viral proteins that may affect viral replication. Recombinant influenza viruses created in the study can be used as vaccines or treatments to reduce virus replication. The application also discusses a method for deleting specific coding sequences in the PB2 gene segment of the influenza virus and replacing them with different protein-encoding sequences. Additionally, the application describes the use of isolated influenza viruses and nucleic acids in preventing or treating influenza infections. [Extracted from the article]

A patent application has been filed for a method of permanently suppressing HIV-1 gene expression in cells through gene editing. The method involves modifying the CCNT1 and XPO1 genes to express proteins with specific amino acid substitutions, rendering the cells resistant to HIV-1 gene expression. The gene editing can be performed using tools such as CRISPR/Cas9, and the edited cells can be reintroduced into the patient's body to outcompete infected cells. This approach has the potential to provide a targeted strategy for curing HIV-1 infection. [Extracted from the article]

The patent application titled "Methods Of Stratifying And Treating Coronavirus Infection" presents a method for treating COVID-19 infections caused by the SARS-CoV-2 virus. The method involves identifying indicators of infection in a sample from a patient and comparing them to control samples to determine the severity of the infection. Based on the severity, appropriate treatments can be administered. The patent application suggests using antiviral, antibiotic, or cholesterol biosynthesis inhibitor drugs for treatment and also explores the use of immune-based therapies. The goal of the method is to provide personalized treatments based on the individual's infection severity. [Extracted from the article]